In breast cancer and multiple myeloma, syndecan-1 overexpression correlates with aggressive phenotype and poor prognosis and was implicated in resistance to either cytotoxic or targeted therapeutics [61,62,114,115,116,117]. Here, SDC1 is linked to AL amyloidosis.